These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 33776366

  • 1. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Nadinskaia M, Maevskaya M, Ivashkin V, Kodzoeva K, Pirogova I, Chesnokov E, Nersesov A, Kaibullayeva J, Konysbekova A, Raissova A, Khamrabaeva F, Zueva E.
    World J Gastroenterol; 2021 Mar 14; 27(10):959-975. PubMed ID: 33776366
    [Abstract] [Full Text] [Related]

  • 2. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis.
    Ozel Coskun BD, Yucesoy M, Gursoy S, Baskol M, Yurci A, Yagbasan A, Doğan S, Baskol G.
    Eur J Gastroenterol Hepatol; 2015 Feb 14; 27(2):142-9. PubMed ID: 25533429
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, Di Marco V, Cammà C, Mensi L, Dongiovanni P, Valenti L, Craxì A, Fargion S.
    Clin Gastroenterol Hepatol; 2017 Oct 14; 15(10):1604-1611.e1. PubMed ID: 28554682
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients.
    Parikh P, Ingle M, Patel J, Bhate P, Pandey V, Sawant P.
    Saudi J Gastroenterol; 2016 Oct 14; 22(3):192-7. PubMed ID: 27184636
    [Abstract] [Full Text] [Related]

  • 7. [Possibilities for the use of ursodeoxycholic acid in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease].
    Rasskazova MA, Vorobyev SV, Butova HN.
    Ter Arkh; 2023 May 31; 95(4):316-321. PubMed ID: 38158979
    [Abstract] [Full Text] [Related]

  • 8. Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in Type 2 Diabetes.
    Wang C, Cai Z, Deng X, Li H, Zhao Z, Guo C, Zhang P, Li L, Gu T, Yang L, Zhao L, Wang D, Yuan G.
    Int J Med Sci; 2021 May 31; 18(14):3280-3289. PubMed ID: 34400897
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy.
    Sanches PL, de Piano A, Campos RM, Carnier J, de Mello MT, Elias N, Fonseca FA, Masquio DC, da Silva PL, Corgosinho FC, Tock L, Oyama LM, Tufik S, Dâmaso AR.
    J Clin Lipidol; 2014 May 31; 8(3):265-72. PubMed ID: 24793347
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Association of subclinical carotid artery atherosclerosis assessed by carotid ultrasound with nonalcoholic fatty liver disease fibrosis score in young and middle-aged men.
    Durak H, Çetin M, Emlek N, Özyıldız AG, Ergül E, Duman H.
    Int J Cardiovasc Imaging; 2024 Sep 31; 40(9):1979-1986. PubMed ID: 39012403
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Atherosclerosis and Associated Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome.
    Bajaj S, Prajapati SK.
    J Assoc Physicians India; 2022 Jun 31; 70(6):11-12. PubMed ID: 35702845
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
    Namkhah Z, Naeini F, Mahdi Rezayat S, Mehdi Yaseri, Mansouri S, Javad Hosseinzadeh-Attar M.
    Int J Clin Pract; 2021 Nov 31; 75(11):e14852. PubMed ID: 34516703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.